Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
The Long Run with Luke Timmerman
Intro
The chapter features a conversation with the CEO of Avidity Biosciences, delving into their innovative approach to RNA medicines targeting muscle diseases. It highlights the company's clinical trial successes and the potential impact of their technology on patient outcomes in conditions like myotonic dystrophy and Duchenne muscular dystrophy.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
